COMMUNIQUÉS West-GlobeNewswire

Transactions In Connection with Share Buy-back Program
07/04/2025
Company Announcement COPENHAGEN, Denmark; April 7, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce [...]
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
07/04/2025
If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, [...]
Reunion Neuroscience Presents REKINDLE, a Phase 2 Clinical Trial Evaluating RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses at the Anxiety & Depression Association of America (ADAA) 2025 Conference
07/04/2025
-- AjD is a Mental Health Condition Triggered By a Stressful Life Event; Particularly Common in People with Serious Medical Illness -- -- AjD Represents an Area of Significant Unmet Need; No FDA-Approved Therapies [...]
Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors
07/04/2025
DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC [...]
Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025
07/04/2025
TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 [...]
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
07/04/2025
CELEBRATION, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Avicanna Announces its 5th Medical Symposium on Cannabinoid-based Medicine
07/04/2025
Bridging Science and Clinical Practice: A Gathering of Thought Leaders in Cannabinoid Medicine Live and Virtual Symposium on June 6 th , 2025, at the MaRS Discovery District, Toronto TORONTO, April 07, 2025 (GLOBE [...]
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals
07/04/2025
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis (MS) and [...]
Kraig Biocraft Laboratories is Happy to Announce its New Director of Molecular Biology as it Accelerates Advanced Fibers Development
07/04/2025
ANN ARBOR, Mich., April 07, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk-based super materials, is pleased to announce the [...]
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
07/04/2025
Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and strategy WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “ [...]
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity
07/04/2025
-- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p<0.0001) -- -- -19.2% placebo-adjusted BMI [...]
ADMA Biologics Statement on Tariffs
07/04/2025
Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain RAMSEY, N.J. and BOCA RATON, Fla., April 07, [...]
Atwater Brewery Releases Atwater Light: Detroit’s Premium Light Craft Beer
07/04/2025
Atwater Light Brings a Crafted Touch to Low-Calorie beer, Inspired by the Spirit of Detroit DETROIT, April 07, 2025 (GLOBE NEWSWIRE) -- Atwater Brewing , Detroit’s renowned craft brewery and a craft beer brand of Tilray [...]
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting
07/04/2025
TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstrated statistically significant improvement in the primary [...]
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
07/04/2025
FRIENDSWOOD, Texas, April 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received a Top [...]
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
07/04/2025
Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelines Enrollment underway in CHAPTER-3, a pivotal [...]
Telix Appoints Paul Schaffer as Chief Technology Officer
07/04/2025
MELBOURNE, Australia and INDIANAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly [...]
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
07/04/2025
HUNTSVILLE, AL, April 07, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology [...]
Transactions under Novonesis’ share buyback program
07/04/2025
Please read the announcement in PDF Attachment 2025_17_Share_buyback_program

Pages